Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$35.87 - $47.12 $514,877 - $676,360
-14,354 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$32.88 - $44.57 $108,273 - $146,769
3,293 Added 29.77%
14,354 $586,000
Q1 2021

May 14, 2021

SELL
$30.92 - $44.4 $246,896 - $354,534
-7,985 Reduced 41.92%
11,061 $363,000
Q4 2020

Feb 12, 2021

BUY
$33.66 - $40.76 $37,598 - $45,528
1,117 Added 6.23%
19,046 $774,000
Q3 2020

Nov 13, 2020

BUY
$33.07 - $38.68 $3,571 - $4,177
108 Added 0.61%
17,929 $656,000
Q2 2020

Aug 19, 2020

SELL
$20.05 - $33.89 $1.69 Million - $2.86 Million
-84,285 Reduced 82.55%
17,821 $604,000
Q2 2020

Aug 14, 2020

BUY
$20.05 - $33.89 $1.86 Million - $3.14 Million
92,594 Added 973.44%
102,106 $28.8 Million
Q4 2019

Feb 13, 2020

BUY
$18.88 - $24.14 $179,586 - $229,619
9,512 New
9,512 $212,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $15.1B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Gqg Partners LLC Portfolio

Follow Gqg Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gqg Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gqg Partners LLC with notifications on news.